/
BDSX
$23.81+$0.47 (+2.01%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$241.7M
10M shares
52-week range
$5.20 – $24.34
97% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
5.64%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-231.79
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.4M | $24.6M | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Cost of revenue | $4.4M | $6.1M | $22.0M | $30.5M | $14.2M | $13.0M | $15.6M | $16.7M |
| Gross profit | $16.0M | $18.5M | $23.6M | $24.0M | $24.1M | $36.1M | $55.8M | $71.8M |
| Gross margin | 78.4% | 75.3% | 51.7% | 44.0% | 63.0% | 73.5% | 78.2% | 81.1% |
| R&D | $8.2M | $10.5M | $10.8M | $12.8M | $13.1M | $10.0M | $9.6M | $12.0M |
| Operating income | −$23.5M | −$26.7M | −$22.9M | −$40.9M | −$50.6M | −$41.3M | −$34.5M | −$27.8M |
| EBITDA | −$21.5M | −$24.9M | −$20.8M | −$35.5M | −$51.5M | −$37.1M | −$29.2M | −$21.9M |
| Net income | −$26.2M | −$30.7M | −$31.4M | −$43.2M | −$65.4M | −$52.1M | −$42.9M | −$35.3M |
| Net margin | -128.1% | -125.1% | -68.8% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
| EPS (diluted) | -19.80 | -0.67 | -6.48 | -31.60 | -31.00 | -12.80 | -6.60 | -4.67 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $111M | $-2.96 | $-3.02–$-2.90 | 5 |
| 2027 | $133M | $-1.77 | $-1.87–$-1.66 | 5 |
| 2028 | $155M | $-1.05 | $-1.45–$-0.65 | 2 |
| 2029 | $182M | $-0.31 | $-0.31–$-0.31 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Biodesix, Inc. Common Stock
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
www.biodesix.com- Employees
- 334
- IPO / List date
- Oct 28, 2020
- HQ
- LOUISVILLE, CO
Held by traders on TradeandTell
No one on the platform currently holds BDSX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 11,948 | $173.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-09-15 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded BDSX yet.
